NASDAQ:PTIE - Pain Therapeutics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $1.11 +0.05 (+4.70 %) (As of 05/24/2019 04:00 PM ET)Previous Close$1.1144Today's Range$1.0725 - $1.139052-Week Range$0.76 - $10.87Volume131,689 shsAverage Volume249,125 shsMarket Capitalization$19.19 millionP/E RatioN/ADividend YieldN/ABeta1.91 ProfileAnalyst RatingsChartDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Pain Therapeutics, Inc. develops drugs for nervous system disorders in the United States. The company's lead drug candidate is REMOXY, a proprietary abuse-deterrent oral formulation of oxycodone to treat severe chronic pain. It is also developing FENROCK, a proprietary abuse-deterrent transdermal pain patch for pain relief; PTI-125, a small molecule drug candidate to treat Alzheimer's disease; and PTI-125DX, a blood-based diagnostic/biomarker to detect Alzheimer's disease. The company was founded in 1998 and is based in Austin, Texas. Receive PTIE News and Ratings via Email Sign-up to receive the latest news and ratings for PTIE and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals SectorMedical Current SymbolNASDAQ:PTIE Previous Symbol CUSIP69562K10 CIK1069530 Webhttp://www.paintrials.com/ Phone512-501-2444Debt Debt-to-Equity RatioN/A Current Ratio24.09 Quick Ratio24.09Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.47 per share Price / Book0.76Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-11,910,000.00 Net MarginsN/A Return on Equity-50.68% Return on Assets-47.15%Miscellaneous Employees9 Outstanding Shares17,220,000Market Cap$19.19 million Next Earnings DateN/A OptionableNot Optionable Pain Therapeutics (NASDAQ:PTIE) Frequently Asked Questions What is Pain Therapeutics' stock symbol? Pain Therapeutics trades on the NASDAQ under the ticker symbol "PTIE." When did Pain Therapeutics' stock split? How did Pain Therapeutics' stock split work? Shares of Pain Therapeutics reverse split on the morning of Wednesday, May 10th 2017. The 1-7 reverse split was announced on Monday, May 8th 2017. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, May 9th 2017. An investor that had 100 shares of Pain Therapeutics stock prior to the reverse split would have 14 shares after the split. How were Pain Therapeutics' earnings last quarter? Pain Therapeutics, Inc. (NASDAQ:PTIE) posted its quarterly earnings results on Monday, March, 25th. The biopharmaceutical company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.61) by $0.57. View Pain Therapeutics' Earnings History. Has Pain Therapeutics been receiving favorable news coverage? Media headlines about PTIE stock have trended negative on Saturday, according to InfoTrie Sentiment. The research group identifies positive and negative press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Pain Therapeutics earned a coverage optimism score of -2.7 on InfoTrie's scale. They also gave press coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the immediate future. Who are some of Pain Therapeutics' key competitors? Some companies that are related to Pain Therapeutics include Apricus Biosciences (APRI), Aridis Pharmaceuticals (ARDS), Vaccinex (VCNX), Nemus Bioscience (NMUS), Adamis Pharmaceuticals (ADMP), NewLink Genetics (NLNK), Aravive (ARAV), Arcturus Therapeutics (ARCT), Acasti Pharma (ACST), SCYNEXIS (SCYX), Elite Pharmaceuticals (ELTP), Sunesis Pharmaceuticals (SNSS), Medicure (MCUJF), OASMIA PHARMACE/ADR (OASM) and IMMUTEP LTD/S (IMMP). What other stocks do shareholders of Pain Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Pain Therapeutics investors own include Synergy Pharmaceuticals (SGYP), Inovio Pharmaceuticals (INO), DURECT (DRRX), Exelixis (EXEL), Advanced Micro Devices (AMD), Amicus Therapeutics (FOLD), ImmunoGen (IMGN), Nektar Therapeutics (NKTR), Tetraphase Pharmaceuticals (TTPH) and Achaogen (AKAO). Who are Pain Therapeutics' key executives? Pain Therapeutics' management team includes the folowing people: Mr. Remi Barbier, Founder, Chairman, CEO & Pres (Age 59)Dr. Nadav Friedmann, COO, Chief Medical Officer & Director (Age 76)Mr. Eric J. Schoen, Chief Financial Officer (Age 51)Dr. Michael Marsman Pharm.D., Sr. VP of Regulatory Affairs How do I buy shares of Pain Therapeutics? Shares of PTIE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Pain Therapeutics' stock price today? One share of PTIE stock can currently be purchased for approximately $1.1144. How big of a company is Pain Therapeutics? Pain Therapeutics has a market capitalization of $19.19 million. Pain Therapeutics employs 9 workers across the globe. What is Pain Therapeutics' official website? The official website for Pain Therapeutics is http://www.paintrials.com/. How can I contact Pain Therapeutics? Pain Therapeutics' mailing address is 7801 NORTH CAPITAL OF TEXAS HIGHWAY SUITE 260, AUSTIN TX, 78731. The biopharmaceutical company can be reached via phone at 512-501-2444 or via email at [email protected] MarketBeat Community Rating for Pain Therapeutics (NASDAQ PTIE)Community Ranking: 2.3 out of 5 ( )Outperform Votes: 189 (Vote Outperform)Underperform Votes: 225 (Vote Underperform)Total Votes: 414MarketBeat's community ratings are surveys of what our community members think about Pain Therapeutics and other stocks. Vote "Outperform" if you believe PTIE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PTIE will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/25/2019 by MarketBeat.com StaffFeatured Article: Trading Strategy Methods for Individual Investors Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.